Neonc Technologies Holdings, Inc. (NTHI)
Oxford Ledge is still expanding full research coverage of NTHI. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Clinical-stage biopharmaceutical company developing brain cancer treatments using intranasal and oral delivery of perillyl alcohol-based drugs.
SEC filings
- 8-K Departure/election of directors or officers 2026-07-02
- DEF 14A Proxy statement for shareholder vote 2026-06-23
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-23
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-18
- 8-K Entry into material agreement; 3.02; 3.03; Amendments to articles or bylaws; Financial statements and exhibits 2026-06-12
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NTHI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NTHI in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.